Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086.

2.

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wählby Hamrén U, Wray H.

Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x.

3.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, Bailey C, Casson E, Cripps D, Cullberg M, Evans S, Foxley A, Lindemann J, Rugman P, Taylor N, Turner G, Yates J, Lawrence P.

Cancer Chemother Pharmacol. 2018 May;81(5):873-883. doi: 10.1007/s00280-018-3558-z. Epub 2018 Mar 14.

4.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

5.

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.

Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, André F.

Clin Cancer Res. 2017 Sep 15;23(18):5366-5373. doi: 10.1158/1078-0432.CCR-17-0645. Epub 2017 Jun 14.

6.

In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.

Johansson S, Löfberg B, Aunes M, Lunde H, Frison L, Edvardsson N, Cullberg M.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):364-73. doi: 10.1002/cpdd.250. Epub 2016 Mar 23.

PMID:
27627192
7.

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P.

Lancet Respir Med. 2016 Oct;4(10):797-806. doi: 10.1016/S2213-2600(16)30227-2. Epub 2016 Aug 27.

PMID:
27574788
8.

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B.

Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.

PMID:
25681277
9.

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Johansson S, Cullberg M, Eriksson UG, Elg M, Dunér K, Jensen E, Wollbratt M, Wåhlander K.

Int J Clin Pharmacol Ther. 2011 Apr;49(4):258-67. doi: 10.5414/CP201465.

PMID:
21429440
10.

[Lymphogranuloma venereum--increased spread in Sweden. A rare Chlamydia subtype which become more and more common among men who have sex with men].

Velicko I, Cullberg M, Bratt G, Mamlöv G, Johnsson A, Hansson HB, Herrmann B, Blaxhult A.

Lakartidningen. 2009 Jan 7-13;106(1-2):28-31. Swedish. No abstract available.

PMID:
19235318
11.

[Rectal and pharyngeal Chlamydia common among men who have sex with men].

Cullberg M, Bratt G, Petrersson F, Karlsson A.

Lakartidningen. 2009 Jan 7-13;106(1-2):24-7. Swedish. No abstract available.

PMID:
19235317
12.

Encapsulation of commercially available losartan for blinding purposes does not affect its bioavailability.

Nyman L, Taure K, Cullberg M, Lagerström PO.

Clin Drug Investig. 1998;15(4):361-5. No abstract available.

PMID:
18370491
13.

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO.

Clin Pharmacol Ther. 2005 Apr;77(4):279-90.

PMID:
15903126
14.

No effect of encapsulation on the pharmacokinetics of warfarin.

Johansson S, Ohlsson L, Stenhoff H, Wåhlander K, Cullberg M.

Biopharm Drug Dispos. 2005 Apr;26(3):121-7.

PMID:
15751004
15.

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.

Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG.

Eur J Clin Pharmacol. 2003 Aug;59(4):283-9. Epub 2003 Jul 4.

PMID:
12845508

Supplemental Content

Loading ...
Support Center